ADF Awards

The ADF announces various prizes to reward scientists / researchers from the field of dermatological research. In addition to the Paul Langerhans Award for established researchers and the Egon Macher Award for young investigators outstanding works in the field of allergy research (ADF / ECARF Award of European Allergy Research) and oncology (Dermato Oncology Junior Scientist Award) will be honored on the ADF Annual Meetings.

In addition, the best posters will be awarded with a poster prize.

For the complete tender texts and the detailed allocation policies please click on the highlighted link.

Please note:
For poster prices, the ADF / ECARF Award for European Allergy Research, the Dermato Oncology Junior Scientist Awards and for the Translational Research Award, a separate application is not necessary. For these prices all abstracts submitted before the deadline will be evaluated.
Submissions for the Paul Langerhans Award and the Egon Macher Award should be made in all cases exclusively in electronic form as one PDF file to the ADF office.
Submission deadline: November 01.


Egon Macher Award of the ADF

- Young Investigator Award - 

sponsored by AbbVie Germany & Co KG

  1. The Egon Macher Award was launched in 2003 and is given every year by the ADF to young investigators for outstanding research contributions in experimental dermatology. 

  2. The award has a volume of 7500 € and can be donated to up to two young investigators. In case the Scientific Awarding Committee is unable to find a suitable candidate among the applicants the award is waived and the amount of money will be added to the Egon Macher Award given in the subsequent year.

  3. Every ADF member not older than 40 years is eligible for application. Candidates that have received other major ADF awards are excluded. Directors of clinical departments are also excluded from application. Only the applicant and the senior author but not any of the coauthors of the awarded publication are the designated awardees.

  4. Only the first author but not any of the coauthors of the submitted publication are eligible to apply for the Egon Macher Award. Only one publication can be submitted per applicant.

  5. The submitted publication should not be older than 1 year. For publications in press applicants must provide a letter from the journal editors confirming that the submitted manuscript is accepted for publication.

  6. Together with the work a letter of confirmation must be submitted stating that all scientific contributors of the publication are properly mentioned either in the title, in footnotes or within the text and that they all agree with the submission of the work for the Egon Macher Award by the applicant.

  7. The majority of the research described in the submitted publication should have been conducted in Germany, Austria or Switzerland.

  8. Submission must be done electronically, via a PDF file, to the ADF office prior to the 1st of November. In addition to the publication and the confirmation letter as outlined above the applicant should submit via a CV and a list of publications as PDFs. The different documents must be combined into a single PDF file.

  9. The ADF office will check all submitted applications for correctness and completeness. Only formally correct applications will be sent out for evaluation by the Scientific Awarding Committee.

  10. The Scientific Awarding Committee will make a suggestion for a suitable candidate. This suggestion will be presented to the ADF board. The evaluation criteria are: relevance, novelty, originality, complexity of methods and depth of scientific work-up, plausibility, quality of the journal and previous scientific achievements of the applicant.

  11. The award is given to the awardee during the Annual Meeting of the ADF.

  12. The awardee is asked to publish a mini review at the ADF home journal Experimental Dermatology (mandatory with acceptance of the award).

    Scientific Awarding Committee:
    • Prof. Dr. Karin Loser (Chair)
    • Prof. Dr. Rüdiger Eming
    • Prof. Dr. Kilian Eyerich
    • Prof. Dr. Evelyn Gaffal
    • Dr. Elsa Neubert
    • Prof. Dr. Ralf Ludwig
    • Prof. Dr. Wolfgang Weninger

Past awardees of the Egon Macher Award of the ADF

Anna Redl, Vienna
Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation (Immunity 56, 1–18, February 14, 2023)

Lukas Leiendecker, Wien
Human papillomavirus 42 drives digital papillary adenocarcinoma and elicits a germ-cell like program conserved in HPV-positive cancers (Cancer Discovery, 10, 2022)

Simona Saluzzo, Vienna
Delayed antiretroviral therapy in HIV-infected individuals leads to irreversible depletion of skin- and mucosa-resident memory T cells

Maike Effern, Bonn
Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context Dependent Immune Evasion in Melanoma

(Immunity 53, 1–17 September 15, 2020)

Johanna Strobl, Wien
Long-term skin resident memory T cells proliferate in situ and are involved in human graft-versus-host disease

(Science Translational Medicine 2020)

Julia Matthias, Berlin
Sodium chloride is an ionic checkpoint for human TH2 cells and shapes the atopic skin microenvironment

Matthias et al., Sci. Transl. Med. 11, eaau0683 (2019) 20 February 2019

Artem Vorobyev, Lübeck
Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line


Elsa Neubert, Göttingen
Cromatin swelling drives neutrophil extracellular trap release

Nicole Glodde, Bonn
Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy

Nadine Lohmann, Leipzig; Lucas Schirmer, Dresden
Glycosaminoglycan-based hydrogels capture inflammatory chemokines and rescue defective wound healing in mice

Xiaolei Ding, Cologne
mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation

Jan P. Nicolay, Mannheim
Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB

Johanna Knipper and Sebastian Willenborg, Cologne/Edinburgh
Interleukin-4 Receptor α signaling in myeloid cells controls collagen fibril assembly in skin repair

Yuliya Skabytska, Tübingen
Cutaneous Innate Immune Sensing of Toll-like Receptor 2-6 Ligands Suppresses T Cell Immunity by Inducing Myeloid-Derived Suppressor Cells

Tobias Bald, Bonn
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma

Maria Carolina Florian, Ulm
A canonical to non-canonical Wnt signalling switch in hematopoietic stem cell ageing (Nature 2013, Oct 20)

David Ellinghaus, Kiel
High-density genotyping study identifies four new susceptibility loci for atopic dermatitis (Nature Genetics 7/2013)

Jenny Landsberg, Judith Kohlmeyer, Marcel Renn, Bonn
Melanomas resist T-cells therapy througt inflammation-induced reversible dedifferentiation (2012 Nature 490, 412-416)

Thomas Wiesner, New York
Germline mutations in BAP1 predispose to melanocytic tumors (Nature Genetics, 2011 Aug:43 (10): 1018-21)

Stefanie und Kilian Eyerich, München
Th22 cells represent a distinct human T lymphocyte subset involved in epidermal immunity and remodeling (J Clin Invest. 2009 Dec;119(12):3573-85)

Jochen Utikal, Mannheim
Cellular immortalization eliminates a roadblock during the reprogramming of somatic cells into iPS cells (Nature. 2009; 460:1145-8.)

Christoffer Gebhardt, Heidelberg
RAGE signaling sustains inflammation and promotes tumor development. (J Exp Med. 2008;205:275-85)

Evelyn Gaffal, Bonn
Attenuation of allergic contact dermatitis through the endocannabinoid system. (Science. 2007;316:1494-7)

Karin Loser, Münster
Epidermal RANKL controls regulatory T-cell numbers via activation of dentritic cells. (Nat Med. 2006;12:1372-9)

Anca Sindrilaru, Thorsten Peters, Ulm
Wound healing defect of CD18 mice due to a decrease in TGF-beta1 and myofibroblast differentiation. (EMBO J. 2005; 24:3400-10)

David Schrama, Würzburg
Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. (Immunity. 2001;14:111-21)

Esther von Stebut, Mainz
Interleukin-1a promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice (J Exp Med. 2003;198:191-9) Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1a/b released from neutrophils recruited by mast cell-derived TNFa (Blood 2003;101:210-5)